Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carmustine + Tebentafusp |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carmustine | Becenun | BCNU | Chemotherapy - Alkylating 18 | Becenun (carmustine) is an antineoplastic alkylating agent, which cross-links DNA and disrupts the cell-cycle (NCI Drug Dictionary). |
| Tebentafusp | Kimmtrak | ImmTAC-gp100|Tebentafusp-tebn|IMCgp100 | Kimmtrak (tebentafusp) is a gp100 antigen-specific human T-cell receptor (TCR) linked to an anti-CD3 antibody fragment, which activates cytotoxic immune response against gp100-expressing tumor cells (PMID: 24531387, PMID: 31336704, PMID: 32816891). Kimmtrak (tebentafusp) is FDA approved for use in HLA-A*2:01-positive metastatic or unresectable uveal melanoma patients (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06626516 | Phase Ib/II | Tebentafusp Sargramostim + Tebentafusp Carmustine + Tebentafusp | Tebentafusp-tebn With LDT in Metastatic UM | Recruiting | USA | 0 |